Financings in Brief: Angiotech Pharmaceuticals
This article was originally published in The Gray Sheet
Angiotech Pharmaceuticals: Grosses $22 mil. from initial public offering of 2.2 mil. common stock shares at $10 each. The Vancouver, British Columbia-based pharmaceutical concern signed a co-exclusive, worldwide licensing agreement in July allowing Boston Scientific and Cook to use the firm's paclitaxel drug technology for stent coatings and with other endoluminal devices ("The Gray Sheet" July 14, I&W-1). Proceeds from the offering are tabbed for "core technology research, product research and product development," Angiotech states. Underwriters First Marathon Securities Limited, Midland Walwyn Capital, and Goepel Shields & Partners hold an overallotment option for 330,000 additional shares...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.